ASCO GI Highlights

Share

Program Content

Activities

Pembro + Lenvatinib + CT for GEC
LEAP-015: Phase III Safety Run-in Data With Pembrolizumab + Lenvatinib + Chemotherapy for Advanced Gastroesophageal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 25, 2023

Expires: January 24, 2024

Zolbetuximab for CLDN18.2+ GEC
SPOTLIGHT: Phase III Study of First-line Zolbetuximab + mFOLFOX6 for Advanced CLDN18.2+/HER2- Gastric/Gastroesophageal Junction Adenocarcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 25, 2023

Expires: January 24, 2024

Nab-Paclitaxel + Gem/Cis for BTCs
SWOG 1815: Phase III Trial of First-line Gemcitabine/Cisplatin ± Nab-Paclitaxel for Advanced Biliary Tract Cancers
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 26, 2023

Expires: January 25, 2024

NALIRIFOX for mPDAC
NAPOLI 3: Phase III Trial of First-line NALIRIFOX vs Nab-Paclitaxel + Gemcitabine for Metastatic Pancreatic Adenocarcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 30, 2023

Expires: January 29, 2024

TAS-102 ± Bev for Refractory mCRC
SUNLIGHT: Phase III Trial of TAS-102 With or Without Bevacizumab for Third-line Treatment of Refractory Metastatic Colorectal Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 30, 2023

Expires: January 29, 2024

HER2 Scoring Systems in mCRC
Concordance Analysis of Gastric and Breast Cancer HER2 Scoring Systems for mCRC From the MOUNTAINEER Phase II Trial
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 30, 2023

Expires: January 29, 2024

Pemigatinib in mCRC
Phase II Study of the FGFR Inhibitor Pemigatinib for Previously Treated Metastatic CRC With FGF/FGFR Alterations
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 30, 2023

Expires: January 29, 2024

CheckMate 649 Update
CheckMate 649 Update: Phase III Study of First-line Nivolumab + CT vs CT for Advanced Gastric/GEJ Cancer and Esophageal Adenocarcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: January 30, 2023

Expires: January 29, 2024

CheckMate 648 Update
CheckMate 648 Update: Phase III Study of First-line Nivolumab + CT vs Nivolumab + Ipilimumab vs CT for Advanced Esophageal Squamous Cell Carcinoma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2023

Expires: February 01, 2024

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Bristol Myers Squibb

Incyte Corporation

Merck Sharp & Dohme Corp.

Seagen Inc.